LyondellBasell Industries closes out September with fresh analyst pressure, a stock down nearly 9% over the past month, and shorts quietly retreating even as the Street turns more cautious.
The most consequential development of the week came on Tuesday morning, when Citigroup downgraded LYB to Neutral from Buy and cut its price target to $63 from $72. The timing matters: the stock is already trading at $58.18, and the downgrade removes one of the few remaining bullish voices at a bellwether firm. UBS followed a similar path days earlier, trimming its neutral target from $64 to $62. Both moves point in the same direction. The Street consensus is a hold, with just two buy ratings against ten holds, and the mean price target of $67.94 implies roughly 17% upside from current levels, though that gap has been compressing steadily as targets have been revised lower through the second half of this year. JPMorgan remains the most constructive voice, sitting at Overweight with an $80 target following an upgrade in early August, but its optimism increasingly looks like an outlier.
What makes the setup unusual is that short sellers are not pressing the bear case with any conviction. Short interest has fallen roughly 8% over the past week to 3.96% of the free float, a level that continued a month-long unwind from a recent peak around 4.4% in mid-September. Borrowing the stock costs next to nothing: 0.56% annually, up 15% from last week but still firmly in "low" territory relative to any meaningful threshold. Availability is extremely loose at more than 8,600%, meaning there are more than 86 shares available to borrow for every one currently borrowed. Anyone who wanted to build a short here faces no supply constraint at all. The ORTEX short score sits at 37.9, drifting lower over the past two weeks from readings around 40, which places LYB in the 32nd percentile of its universe on short positioning. That is not the profile of a stock where bears are crowding in.
Options positioning tells a more defensive story, though without any acute alarm. The put/call ratio is 1.69, slightly below its 20-day average of 1.77, and well off the 52-week high of 2.12 hit just last week. In other words, the heaviest protective activity came and went before the Citi downgrade landed, and options markets have since become marginally less skewed toward puts, even as the stock kept falling. The 52-week low on the PCR is 0.73, highlighting just how structurally put-heavy this name has been all year.
On valuation, LYB is not expensive relative to the earnings it is generating. The trailing P/E is 8.3x, down from 8.76x a month ago, and the EV/EBITDA multiple is 6.6x, which also reflects the declining stock price. The bear case from analysts centres on structural headwinds: a 53% drop in North American Olefins and Polyolefins margins, weak European demand, and oversupply in key product lines including styrene and oxyfuels. The bull case is real but contingent, requiring an improvement in Chinese demand and feedstock cost moderation to push EBITDA toward the $4.5 billion range. Neither scenario looks imminent. EPS momentum over the past 30 days ranks in the 10th percentile, and the 90-day reading ranks in the 12th, making this one of the weaker earnings-revision pictures in the sector right now. Earnings are due on October 30, and the forward earnings yield score of 78 out of 100 suggests the market is at least partially pricing in the weakness.
Ownership is stable at the top of the register. Access Industries, via LYB Holdco LLC, holds a 20.3% stake and has filed a Schedule 13D, placing an activist on the register. That stake has been unchanged since the last disclosure in June 2025, and Schedule 13D positions are event-driven disclosures around the 5% threshold, so the figure should be read as "as last disclosed" rather than current. BlackRock added a meaningful 4.2 million shares as of end-August, bringing its stake to roughly 9%. Dodge & Cox, notably, appears to have almost entirely exited a position that stood at 5.2% earlier in the year, reducing to near zero by its August filing.
Peer names also had a rough week. DOW fell 2.1% and CE dropped 5.5%, while LXU lost more than 8%. LYB's 1.8% weekly decline is comparatively modest, but the company has lost 8.6% over the past month. With Q3 earnings 30 days away, the primary focus shifts to whether management has anything concrete to say about the North American O&P recovery timeline and whether cost reduction initiatives are running ahead of or behind the margin pressure.
See the live data behind this article on ORTEX.
Open LYB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
